fda drug safety communication semaglutide naion 2025 Novo Nordisk expands legal action to protect US patients from unsafe, non- FDA-approved compounded "semaglutide" FDA Decisions Expected: October 2025

Those savings aside, customers should not expect a meaningful slowing of the ever-rising cost of coverage, Blue Cross chief actuary Mike Guerriere said

In the past, the FDA has sought court orders to force some compounding pharmacies to stop production after repeated failures in sterile drug manufacturing

Studies in mice with CNS neuron-specific GLP-1R knockout showed that liraglutide failed to induce weight loss but still improved glucose levels, suggesting that brain GLP-1Rs are necessary for the weight-lowering effect of GLP-1RAs but not essential for their glucose-lowering effects (142)

Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs